Key stats
About iShares NASDAQ US Biotechnology UCITS ETF
Home page
Inception date
Oct 19, 2017
Structure
Irish VCIC
Replication method
Physical
Dividend treatment
Capitalizes
Primary advisor
BlackRock Asset Management Ireland Ltd.
ISIN
IE00BYXG2H39
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.87%
Health Technology95.29%
Finance1.59%
Commercial Services1.19%
Technology Services1.09%
Health Services0.69%
Process Industries0.03%
Bonds, Cash & Other0.13%
Cash0.07%
Mutual fund0.05%
Stock breakdown by region
North America82.17%
Europe17.36%
Asia0.41%
Oceania0.06%
Latin America0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
BTEK invests in stocks. The fund's major sectors are Health Technology, with 95.29% stocks, and Finance, with 1.59% of the basket. The assets are mostly located in the North America region.
BTEK top holdings are Vertex Pharmaceuticals Incorporated and Amgen Inc., occupying 7.72% and 7.63% of the portfolio correspondingly.
BTEK assets under management is 391.54 M GBP. It's risen 25.79% over the last month.
BTEK fund flows account for 13.22 M GBP (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, BTEK doesn't pay dividends to its holders.
BTEK shares are issued by BlackRock, Inc. under the brand iShares. The ETF was launched on Oct 19, 2017, and its management style is Passive.
BTEK expense ratio is 0.35% meaning you'd have to pay 0.35% of your investment to help manage the fund.
BTEK follows the NASDAQ Biotechnology Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
BTEK invests in stocks.
BTEK price has risen by 4.52% over the last month, and its yearly performance shows a −10.92% decrease. See more dynamics on BTEK price chart.
NAV returns, another gauge of an ETF dynamics, showed a 9.85% increase in three-month performance and has decreased by −11.79% in a year.
NAV returns, another gauge of an ETF dynamics, showed a 9.85% increase in three-month performance and has decreased by −11.79% in a year.
BTEK trades at a premium (1.23%) meaning the ETF is trading at a higher price than the calculated NAV.